Lotilaner Patent Expiration
Lotilaner is Used for treating demodex blepharitis by applying topically to the eye surface. It was first introduced by Tarsus Pharmaceuticals Inc
Lotilaner Patents
Given below is the list of patents protecting Lotilaner, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xdemvy | US10835517 | Methods for treating ocular demodex using isoxazoline parasiticide formulations | Dec 14, 2038 | Tarsus |
| Xdemvy | US11197847 | Isoxazoline parasiticide formulations and methods for treating blepharitis | Dec 14, 2038 | Tarsus |
| Xdemvy | US11690826 | Methods for treating demodex blepharitis using lotilaner formulations | Dec 14, 2038 | Tarsus |
| Xdemvy | US11690827 | Methods for treating ocular Demodex using lotilaner formulations | Dec 14, 2038 | Tarsus |
| Xdemvy | US11752137 | Ophthalmic compositions for treating ocular Demodex using lotilaner formulations | Dec 14, 2038 | Tarsus |
| Xdemvy | US8383659 | Isoxazoline derivatives as pesticides | Jan 17, 2030 | Tarsus |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lotilaner's patents.
Latest Legal Activities on Lotilaner's Patents
Given below is the list recent legal activities going on the following patents of Lotilaner.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 14 May, 2024 | US10835517 |
| Recordation of Patent Grant Mailed Critical | 12 Sep, 2023 | US11752137 |
| Mail Patent eGrant Notification | 12 Sep, 2023 | US11752137 |
| Patent eGrant Notification | 12 Sep, 2023 | US11752137 |
| Email Notification Critical | 12 Sep, 2023 | US11752137 |
| Recordation of Patent eGrant | 12 Sep, 2023 | US11752137 |
| Patent Issue Date Used in PTA Calculation Critical | 12 Sep, 2023 | US11752137 |
| Email Notification Critical | 24 Aug, 2023 | US11752137 |
| Issue Notification Mailed Critical | 23 Aug, 2023 | US11752137 |
| Application Is Considered Ready for Issue Critical | 27 Jul, 2023 | US11752137 |
Lotilaner's Family Patents
